The following is a statement from Allergy & Asthma Network President and CEO Tonya Winders on the possible shortage of EpiPens and Adrenaclick epinephrine auto-injectors announced by the Food and Drug Administration (FDA):
“On May 9, 2018, FDA announced documented spot shortages of EpiPens, generic EpiPens and Adrenaclick epinephrine auto-injectors. While this is concerning, it is important to note that we have received very few reports of limited access in the U.S. thus far and people should not panic.
“It is important for families and providers to remember to check the expiration dates on auto-injectors and plan ahead to secure refills. If you encounter a shortage, remember there are more options than ever before. Providers should speak with patients about these options and determine which one is best. Training on specific auto-injectors is critically important because in the midst of a severe allergic reaction it is important to be confident how to use the device on hand.
“If you experience access challenges or spot shortages, please notify the manufacturer and also feel free to let us know at the Network as we can help identify an available outlet in your area.”